Senzagen is a leading brand in the field of non-animal testing for assessing the toxicity of substances. They offer a range of high-performance, human-relevant test methods and advisory services that contribute to safer and more sustainable products in the market. By utilizing state-of-the-art technology, Senzagen aims to replace animal testing with innovative in vitro technology that better reflects human biological reactions to toxic substances.

Their flagship test platform, GARD®, uses genomics and machine learning to determine whether substances can cause allergic reactions. This method has greater predictive accuracy than traditional animal-based methods. Additionally, Senzagen recently acquired VitroScreen, which specializes in human 3D tissue models, expanding their testing capabilities.

Senzagen's growth strategy includes the commercialization of their test platforms, expansion of their test portfolio, and acquisitions of complementary companies. With a global and rapidly growing market for in vitro toxicology testing, Senzagen estimates their addressable market at approximately SEK 30 billion. By choosing Senzagen, you can be assured of safer products in society, improved production environments, and a reduced reliance on animal testing